TCG Labs Soleil Advances Three Clinical Programs

SAN FRANCISCO, Oct. 28, 2026 /CourierPR/ -- TCG Labs Soleil, a venture-biotech organization integrating dedicated capital with an in-house R&D hub, has announced significant portfolio momentum with three independent portfolio companies now in first-in-human Phase 1 clinical trials. The organization’s centralized in-house R&D hub has rapidly built a deep portfolio that now includes 19 portfolio companies since its launch in 2024. The advancement of three molecules into Phase 1 clinical trials represents the first wave of TCG Labs Soleil’s clinical portfolio, with additional programs, including a chronic inflammatory respiratory candidate, rapidly progressing toward the clinic.

The clinical programs represent the first wave of TCG Labs Soleil’s portfolio companies of clinically enabled opportunities spanning oncology, immunology, cardiovascular disease, and other areas of significant unmet need.

Duboce Biopharmaceuticals, a portfolio company of TCG Labs Soleil, is evaluating DBC-664 in a first-in-human, Phase 1a/1b, open-label, multicenter clinical trial in adults with relapsed or refractory, unresectable locally advanced or metastatic solid tumors associated with ALPP or ALPPL2 expression. Duboce’s DBC-664 is an investigational ALPP/L2-directed T-cell engager designed to target antigens that are highly expressed in a variety of difficult-to-treat solid tumors, most homogeneously in ovarian and endometrial cancers. By targeting these specific antigens, DBC-664 aims to provide a favorable therapeutic index for patients with advanced cancers who otherwise have limited effective treatment options in the relapsed or refractory setting.

Juri Biosciences, another portfolio company, is evaluating JUR-003 in adults with metastatic prostate cancer in a first-in-human, Phase 1a/1b, open-label, multicenter clinical trial. JUR-003 is the lead program in Juri’s portfolio of differentiated KLK2-directed T-cell engagers. It is an investigational bispecific monoclonal antibody designed to recruit T cells to prostate cancer cells expressing KLK2, a highly specific prostate cancer target with minimal expression outside prostate tissue. JUR-003 is designed for subcutaneous administration, a profile that may be particularly relevant in earlier disease settings where patients may receive treatment over longer periods. Its profile is also intended to support combination with other treatment modalities across multiple prostate cancer settings.

Arguello Biosciences is currently evaluating ARG-397 in healthy adult participants in a Phase 1, randomized, single-blind, placebo-controlled, single-ascending dose clinical trial. ARG-397 is an investigational, highly potent half-life-extended Factor XI monoclonal antibody being developed as a potential best-in-class durable anticoagulation approach for thromboembolic disorders, including chronic conditions such as atrial fibrillation. Factor XI inhibition is intended to reduce pathological clot formation while preserving important elements of normal hemostasis, offering the potential to address bleeding concerns associated with current anticoagulant therapies. ARG-397 has the potential to combine a robust degree of anticoagulation with less frequent dosing, an important consideration for patients who require long-term anticoagulation therapy.

Clement Therapeutics is advancing CMT-133, an α-TSLP x α-IL-33 bispecific antibody being developed for chronic inflammatory respiratory diseases, including COPD, asthma, and other inflammatory respiratory diseases. CMT-133 is designed to target two upstream alarmins implicated in respiratory inflammation, with the goal of treating both Type 2 high and Type 2 low patient populations, and supporting future use as monotherapy or in combination with other treatment approaches. Preclinical data from CMT-133 were recently presented at the European Respiratory Society Congress 2026. CMT-133 has completed IND-enabling studies and is rapidly advancing toward a first-in-human clinical trial this year, representing the next wave of TCG Labs Soleil’s portfolio progress and continued productivity of its in-house R&D engine.

TCG Labs Soleil combines dedicated capital, scientific expertise, and company-building capabilities to discover, build, and advance differentiated therapeutic programs from discovery and up to early clinical development. Each program is housed within an independent portfolio company and developed with a path toward clinical validation and potential strategic partnership.